Gremlin, a bone morphogenetic protein antagonist, is a crucial angiogenic factor in pituitary adenoma

International Journal of Endocrinology

Volumn 2015, Issue , 2015, Pages

  Koketsu, Kenta ^a   Yoshida, Daizo ^a   Kim, Kyongsong ^a   Ishii, Yudo ^a   Tahara, Shigeyuki ^a   Teramoto, Akira ^a   Morita, Akio ^a  

^a NIPPON MEDICAL SCHOOL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENIC FACTOR; BONE MORPHOGENETIC PROTEIN ANTAGONIST; CD34 ANTIGEN; GLYCOPROTEIN; GREMLIN; PROTEIN INHIBITOR; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; AGED; ARTICLE; CAPILLARY DENSITY; CLINICAL ARTICLE; CORRELATION ANALYSIS; FEMALE; FLUORESCENCE; HUMAN; HUMAN TISSUE; HYPOPHYSIS ADENOMA; IMMUNOFLUORESCENCE MICROSCOPY; IMMUNOHISTOCHEMISTRY; MALE; MICROARRAY ANALYSIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; TISSUE MICROARRAY; TUMOR VASCULARIZATION;

EID: 84925430972     PISSN: 16878337     EISSN: 16878345     Source Type: Journal    
DOI: 10.1155/2015/834137     Document Type: Article

References (38)

1. W. Lederle, M. Palmowski, and F. Kiessling, "Imaging in the age ofmolecular medicine:monitoring of anti-angiogenic treatments, " Current Pharmaceutical Biotechnology, vol. 13, no. 4, pp. 595-608, 2012.
2. A. G. Linkous and E. M. Yazlovitskaya, "Novel therapeutic approaches for targeting tumor angiogenesis, " Anticancer Research, vol. 32, no. 1, pp. 1-12, 2012.
3. B. Shan, C. Schaaf, A. Schmidt et al. , "Curcumin suppresses HIF1A synthesis and VEGFA release in pituitary adenomas, " Journal of Endocrinology, vol. 214, no. 3, pp. 389-398, 2012.
4. J. Yang, Z. Xiao, T. Li, X. Gu, and B. Fan, "Erythropoietin promotes the growth of pituitary adenomas by enhancing angiogenesis, " International Journal of Oncology, vol. 40, no. 4, pp. 1230-1237, 2012.
5. Q. Zhang, Y. Zhang, S. Z. Wang et al. , "Reduced expression of tissue factor pathway inhibitor-2 contributes to apoptosis and angiogenesis in cervical cancer, " Journal of Experimental and Clinical Cancer Research, vol. 31, no. 1, article 1, 2012.
6. X. Zhao, D. C. Li, H. Zhao et al. , "A study of the suppressive effect on human pancreatic adenocarcinoma cell proliferation and angiogenesis by stable plasmid-based siRNA silencing of c-Src gene expression, " Oncology Reports, vol. 27, no. 3, pp. 628-636, 2012.
7. J. T. Zhang, Y. Z. Fan, C. Q. Chen, Z. M. Zhao, and W. Sun, "Norcantharidin: a potential antiangiogenic agent for gallbladder cancers in vitro and in vivo, " International Journal of Oncology, vol. 40, no. 5, pp. 1501-1514, 2012.
8. C. Onofri, M. Losa, E. Uhl, G. K. Stalla, and U. Renner, "Immunohistochemical analysis of VEGF-C/VEGFR-3 system and lymphatic vessel extent in normal and adenomatous human pituitary tissues, " Experimental and Clinical Endocrinology and Diabetes, vol. 116, no. 3, pp. 152-157, 2008.
9. C. Onofri, M. Theodoropoulou, M. Losa et al. , "Localization of vascular endothelial growth factor (VEGF) receptors in normal and adenomatous pituitaries: detection of a non-endothelial function of VEGF in pituitary tumours, " Journal of Endocrinology, vol. 191, no. 1, pp. 249-261, 2006.
10. H. Horiguchi, L. Jin, K. H. Ruebel, B. W. Scheithauer, and R. V. Lloyd, "Regulation of VEGF-A, VEGFR-I, thrombospondin-1,-2, and-3 expression in a human pituitary cell line (HP75) by TGFβ1, bFGF, and EGF, " Endocrine, vol. 24, no. 2, pp. 141-146, 2004.
11. M. C. Zatelli, D. Piccin, C. Vignali et al. , "Pasireotide, amultiple somatostatin receptor subtypes ligand, reduces cell viability in non-functioning pituitary adenomas by inhibiting vascular endothelial growth factor secretion, " Endocrine-Related Cancer, vol. 14, no. 1, pp. 91-102, 2007.
12. C. S. Kim, H. Ying, M. C. Willingham, and S. Y. Cheng, "The pituitary tumor-transforming gene promotes angiogenesis in a mouse model of follicular thyroid cancer, " Carcinogenesis, vol. 28, no. 5, pp. 932-939, 2007.
13. D. S. Kim, J. A. Franklyn, K. Boelaert, M. C. Eggo, J. C. Watkinson, and C. J. McCabe, "Pituitary tumor transforming gene (PTTG) stimulates thyroid cell proliferation via a vascular endothelial growth factor/kinase insert domain receptor/ inhibitor of DNA binding-3 autocrine pathway, " Journal of Clinical Endocrinology andMetabolism, vol. 91, no. 11, pp. 4603-4611, 2006.
14. D. S. Kim, J. A. Franklyn, A. L. Stratford et al. , "Pituitary tumortransforming gene regulates multiple downstream angiogenic genes in thyroid cancer, " The Journal of Clinical Endocrinology andMetabolism, vol. 91, no. 3, pp. 1119-1128, 2006.
15. J. Xu, S. Zhang, C. You, X. Wang, and Q. Zhou, "Microvascular density and vascular endothelial growth factor have little correlation with prognosis of craniopharyngioma, " Surgical Neurology, vol. 66, supplement 1, pp. S30-S34, 2006.
16. H. Stabile, S. Mitola, E. Moroni et al. , "Bone morphogenic protein antagonist Drm/gremlin is a novel proangiogenic factor, " Blood, vol. 109, no. 5, pp. 1834-1840, 2007.
17. C. Ravelli, S. Mitola, M. Corsini, and M. Presta, "Involvement of alpha(v)beta (3) integrin in gremlin-induced angiogenesi, " Angiogenesis, vol. 16, no. 1, pp. 235-243, 2013.
18. L. Claesson-Welsh, "Gremlin: vexing VEGF receptor agonist, " Blood, vol. 116, no. 18, pp. 3386-3387, 2010.
19. D. Maiolo, S. Mitola, D. Leali et al. , "Role of nanomechanics in canonical and noncanonical pro-angiogenic ligand/VEGF receptor-2 activation, " Journal of the American Chemical Society, vol. 134, no. 35, pp. 14573-14579, 2012.
20. E. Tzahor, H. Kempf, R. C. Mootoosamy et al. , "Antagonists of Wnt and BMP signaling promote the formation of vertebrate head muscle, " Genes and Development, vol. 17, no. 24, pp. 3087-3099, 2003.
21. M. S. Mulvihill, Y.-W. Kwon, S. Lee et al. , "Gremlin is overexpressed in lung adenocarcinoma and increases cell growth and proliferation in normal lung cells, " PLoS ONE, vol. 7, no. 8, Article ID e42264, 2012.
22. J. Heinke, M. Juschkat, A. Charlet et al. , "Antagonism and synergy between extracellular BMP modulators Tsg and BMPER balance blood vessel formation, " Journal of Cell Science, vol. 126, no. 14, pp. 3082-3094, 2013.
23. M.-H. Chen, Y.-C. Yeh, Y.-M. Shyr et al. , "Expression of gremlin 1 correlates with increased angiogenesis and progression-free survival in patients with pancreatic neuroendocrine tumors, " Journal of Gastroenterology, vol. 48, no. 1, pp. 101-108, 2013.
24. E. Gazzerro, R. C. Pereira, V. Jorgetti, S. Olson, A. N. Economides, and E. Canalis, "Skeletal overexpression of gremlin impairs bone formation and causes osteopenia, " Endocrinology, vol. 146, no. 2, pp. 655-665, 2005.
25. O. Michos, A. Goncalves, J. Lopez-Rios et al. , "Reduction of BMP4 activity by gremlin 1 enables ureteric bud outgrowth and GDNF/WNT11 feedback signalling during kidney branching morphogenesis, " Development, vol. 134, no. 13, pp. 2397-2405, 2007.
26. E. Gazzerro, A. Smerdel-Ramoya, S. Zanotti et al. , "Conditional deletion of gremlin causes a transient increase in bone formation and bone mass, "The Journal of Biological Chemistry, vol. 282, no. 43, pp. 31549-31557, 2007.
27. D. C. Genetos, C. A. Toupadakis, L. F. Raheja et al. , "Hypoxia decreases sclerostin expression and increases Wnt signaling in osteoblasts, " Journal of Cellular Biochemistry, vol. 110, no. 2, pp. 457-467, 2010.
28. S. Mitola, C. Ravelli, E. Moroni et al. , "Gremlin is a novel agonist of the major proangiogenic receptor VEGFR2, " Blood, vol. 116, no. 18, pp. 3677-3680, 2010.
29. J. B. Sneddon, H. H. Zhen, K. Montgomery et al. , "Bone morphogenetic protein antagonist gremlin 1 is wideley expressed by cancer-associated stromal cells and can promote tumor cell proliferation, " Proceedings of theNational Academy of Sciences of the United States of America, vol. 103, no. 40, pp. 14842-14847, 2006.
30. V. Dolan, M. Murphy, P. Alarcon, H. R. Brady, and C. Hensey, "Gremlin-a putative pathogenic player in progressive renal disease, " ExpertOpinion onTherapeutic Targets, vol. 7, no. 4, pp. 523-526, 2003.
31. D. W. P. Lappin, R. McMahon, M. Murphy, and H. R. Brady, "Gremlin: an example of the re-emergence of developmental programmes in diabetic nephropathy, " Nephrology Dialysis Transplantation, vol. 17, supplement 9, pp. 65-67, 2002.
32. Y. Zhang and Q. Zhang, "Bone morphogenetic protein-7 and Gremlin: new emerging therapeutic targets for diabetic nephropathy, " Biochemical and Biophysical Research Communications, vol. 383, no. 1, pp. 1-3, 2009.
33. D. W. Walsh, S. A. Roxburgh, P. McGettigan et al. , "Coregulation of Gremlin and Notch signalling in diabetic nephropathy, " Biochimica et Biophysica Acta-Molecular Basis of Disease, vol. 1782, no. 1, pp. 10-21, 2008.
34. V. Dolan, M. Murphy, D. Sadlier et al. , "Expression of gremlin, a bone morphogenetic protein antagonist, in human diabetic nephropathy, " American Journal of Kidney Diseases, vol. 45, no. 6, pp. 1034-1039, 2005.
35. R. Kane, L. Stevenson, C. Godson, A. W. Stitt, and C. OBrien, "Gremlin gene expression in bovine retinal pericytes exposed to elevated glucose, " British Journal of Ophthalmology, vol. 89, no. 12, pp. 1638-1642, 2005.
36. C. Gaston-Massuet, C. L. Andoniadou, M. Signore et al. , "Increased Wingless (Wnt) signaling in pituitary progenitor/ stem cells gives rise to pituitary tumors in mice and humans, " Proceedings of the National Academy of Sciences of the United States of America, vol. 108, no. 28, pp. 11482-11487, 2011.
37. A. Giles, F. Madec, S. Friedrichsen et al. , "Wnt signaling in estrogen-induced lactotroph proliferation, " Journal of Cell Science, vol. 124, no. 4, pp. 540-547, 2011.
38. M. S. Elston and R. J. Clifton-Bligh, "Identification of Wnt family inhibitors: a pituitary tumor directedwhole genome approach, " Molecular and Cellular Endocrinology, vol. 326, no. 1-2, pp. 48-54, 2010.